Posts

Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19

on

F2G and Shionogi Report Positive Phase 3 Results for Oral Antifungal Olorofim in Invasive Aspergillosis

on

Shionogi's COVID Antiviral Xocova Approved by FDA as Post‑Exposure Preventive for COVID-19 in the U.S.

on

Shionogi Receives $119M BARDA Award to Establish US Antibiotic Manufacturing Plant

on

Shionogi to Acquire Apnimed's 50% Stake in Sleep Science Joint Venture for $100M Upfront

on

Pfizer Exits ViiV Healthcare as Shionogi Doubles Stake in $2.13 Billion Deal

on

Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma

on